649557-55-1

Basic information

• Product Name: ethyl 4-(4-cyanophenyl)-2,4-dioxobutanoate
• Synonyms: ethyl 4-(4-cyanophenyl)-2,4-dioxobutanoate;Ethyl 4-cyano-a,g-dioxo-benzenebutanoate
• CAS NO: 649557-55-1
• Molecular Formula: C₁₃H₁₁NO₄
• Molecular Weight: 245.23074
• Mol File: 649557-55-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 4-(4-cyanophenyl)-2,4-dioxobutanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(4-cyanophenyl)-2,4-dioxobutanoate(649557-55-1)
• EPA Substance Registry System: ethyl 4-(4-cyanophenyl)-2,4-dioxobutanoate(649557-55-1)

Safety Data

• Hazardous Substances Data: 649557-55-1(Hazardous Substances Data)

Upstream product

• 1443-80-7 4-cyanophenyl methyl ketone 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 649557-56-2 ethyl 3(5)?(4?cyanophenyl)?1H?pyrazole?5(3)?carboxylate 

Relevant articles and documents

Diphenylpyrazoles as replication protein A inhibitors

Replication Protein A is the primary eukaryotic ssDNA binding protein that has a central role in initiating the cellular response to DNA damage. RPA recruits multiple proteins to sites of DNA damage via the N-terminal domain of the 70 kDa subunit (RPA70N). Here we describe the optimization of a diphenylpyrazole carboxylic acid series of inhibitors of these RPA-protein interactions. We evaluated substituents on the aromatic rings as well as the type and geometry of the linkers used to combine fragments, ultimately leading to submicromolar inhibitors of RPA70N protein-protein interactions.

Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor

A series of 3-aryl-5-acylpiperazinyl-pyrazoles (e.g., 3a-b) initially identified through a high-throughput screening campaign using the aequorin Ca2+ bioluminescence assay as novel, potent small molecule antagonists of the G protein-coupled hum

ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA

This invention relates to novel compounds which up-regulate LDL receptor (LDL-r) expression and to processes for their preparation, pharmaceutical compositions containing them and their medical use. More particularly, this invention relates to novel aromatic piperidines of formula (I) and their use in therapy.

Studies on anti-inflammatory agents. IV. Synthesis and pharmacological properties of 1,5-diarylpyrazoles and related derivatives

A series of novel 1,5-diarylpyrazole derivatives was synthesized and tested for anti-inflammatory and analgesic activities to develop anti- inflammatory agents with fewer side effects than existing nonsteroidal anti- inflammatory drugs. The structure-activity relationships in this series were extensively studied. Electron-withdrawing substituents such as CN and CF3 were optimal at the 3-position of the pyrazole ring. Replacement of these substituents with bulky ones gave less active compounds. The 4- (methylsulfonyl)phenyl group seemed to be the optimal group at the 5-position of the pyrazole ring. The most potent compound was 1-(4-fluorophenyl)-5-[4- (methylsulfonyl)phenyl]-pyrazole-3-carbonitrile (19a), with oral ED50 values of 0.030 and 0.47 mg/kg on adjuvant-induced arthritis and collagen- induced arthritis, respectively, and an ED30 value of 7.4 mg/kg in the yeast-induced hyperalgesia (Randall-Selitto) assay. Compound 19a also showed potent inducible cyclooxygenase (COX-2)-inhibitory activity (IC50=0.24μm) with no COX-1 inhibition even at 100μM.